Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NIR178 + PDR001 in advanced solid tumors and non-Hodgkin lymphoma
2017-000241-49Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of taminadenant and spartalizumab in advanced nonhematological malignancy, non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 1 more, sponsored by Novartis. Started Jul 2017; status: terminated.
02
Drugs
taminadenantspartalizumab
03
Conditions
advanced nonhematological malignancynon-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)Non-hematologic malignancy
Beyond the preview
Go deeper on 2017-000241-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000241-49.